(News Bulletin 247) – Neovacs announced Thursday that it has taken a new step in the framework of its strategic partnership signed with the American Biosense Global in the treatment of lupus.
The New Jersey-based group has indeed received positive feedback and a green light from the Chinese health authority, the NMPA, to submit a registration dossier.
Biosense has therefore entered a new phase with the preparation of the marketing application, which has led it to initiate a search for partners in order to financially support the next stages of its development.
As a reminder, just a year ago, Neovacs and Biosense signed a partnership agreement for the technology transfer of the product IFNα Kinoid in the treatment of lupus.
This agreement presented as ‘win-win’ ensures the continuation of the IFNα Kinoid program in lupus on the basis of the results of the phase IIb carried out by Neovacs.
The agreement provides for the resumption of clinical trials in China, fully supported by Biosense Global, while offering Neovacs a new perspective for the valuation of a strategic asset at no cost.
After jumping at the start of the session, Neovacs shares were stable on Thursday on the Paris Stock Exchange as we approached the middle of the session.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
